Revolutionizing Alzheimer’s Disease Clinical Trials Using a Blood-Based Diagnostic Test for Participant Identification

Alzheimer’s disease and other dementias are devastating neurodegenerative disorders affecting more than 55 million people worldwide and have been challenging to detect in early stages.

In this webinar, the featured speaker will explain how this new blood-based test works and the promise it holds for identifying individuals at risk of developing Alzheimer’s disease even before the onset of noticeable symptoms and irreparable brain damage occurs.

One of the significant implications of this test lies in its potential for pharmaceutical companies conducting clinical trials. By identifying suitable participants in the early stages, participation and intervention can occur sooner, allowing for more effective treatments to be developed and tested. This webinar will delve into the various ways this blood-based diagnostic test can assist pharma companies in identifying individuals who are more likely to benefit from novel therapeutic interventions.

During this webinar, esteemed Neurology expert, Dr. Michael Racke, will explore the scientific basis of the blood-based diagnostic test, its reliability and its potential impact, offering a less-invasive and more accessible tool that could transform the landscape of Alzheimer’s research.

Join this exclusive webinar and be at the forefront of the latest advancements in Alzheimer’s disease research. Discover how this blood-based diagnostic test has the power to enhance clinical trials, ushering in a new era of early intervention and hope for individuals affected by Alzheimer’s disease.

This is a recording from a live webinar series in collaboration with Xtalks that was originally held on August 24, 2023.

Posted on the CEC on January 25th, 2024